Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever
神经保护性抗炎药物作为神经裂谷热的新型联合疗法
基本信息
- 批准号:9915980
- 负责人:
- 金额:$ 33.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAfricaAgricultureAnimal Disease ModelsAnimal ModelAnimalsAnti-Inflammatory AgentsAntiviral AgentsAnxietyArbovirus InfectionsArbovirusesBiological ModelsBlood - brain barrier anatomyBlood VesselsBrain DiseasesCCL2 geneCell CommunicationCell Culture SystemCellsCellular AssayCentral Nervous System Viral DiseasesCessation of lifeClinicalClinical TrialsCombined Modality TherapyCommunicable DiseasesCommunitiesCulicidaeDataDengueDiseaseDisease OutbreaksDisease OutcomeDisease modelDrug usageEbolaEconomicsEncephalitisEpidemicEventExposure toFeverFrightFutureGelatinase BGoalsHemorrhageHepaticHumanImaging TechniquesImmuneImmunocompetentImmunomodulatorsIndustryInfectionInfiltrationInflammationInflammation MediatorsInflammatoryInflammatory ResponseInfluenzaKineticsLewis Blood-Group SystemLivestockMacrophage Colony-Stimulating FactorMatrix MetalloproteinasesMediatingMiddle EastModelingMonkeysMorbidity - disease rateNervous System TraumaNeuraxisNeurologicNeurologic SymptomsNeuronsNeuroprotective AgentsOncologyOnset of illnessPathogenesisPatientsPharmaceutical PreparationsPharmacotherapyPrimary Cell CulturesProductionPublic HealthRattusRegimenRift Valley FeverRift Valley fever virusRiskRoleSurvivorsTestingTherapeuticTherapeutic InterventionTissuesTreatment ProtocolsVaccine TherapyVaccinesViralViral EncephalitisVirulentVirusVirus ReplicationZIKAblood-brain barrier disruptioncell typechemokinecytokinedesigneffective therapyhuman diseaseimmunopathologyin vitro Modelinduced pluripotent stem cellnervous system disorderneuron apoptosisneuropathologynovelnovel therapeuticspathogenpreventpublic health emergencystem cellstherapeutic candidatevector mosquito
项目摘要
PROJECT SUMMARY/ABSTRACT
Understanding the pathogenesis of neurological disorders caused by arboviruses is fundamental to the
treatment of viral encephalitis using drug or vaccine therapy. Rift Valley Fever (RVF) is a globally-important
emerging mosquito-transmitted disease that presents a significant risk to humans and livestock communities.
The potential for global spread is high due to the pervasive mosquito vectors, and emergence would cause
considerable economic damage (due to the agricultural impact) as well as fear and anxiety (due to human
illness). The most understudied clinical disease caused by RVFV is encephalitis, which causes long-term
morbidity in survivors as well as death in 50% of patients with neurological symptoms. This proposal is founded
upon 3 scientific findings from our preliminary data: 1) There are appropriate encephalitic disease animal models
after infection with a wild-type virulent strain of RVFV; 2) Overproduction of cytokines, chemokines, and matrix
metalloproteinases (MMPs) correlates with neurological disease onset; and 3) Treatment with the antiviral
therapeutic drug favipiravir is necessary but not sufficient to protect animals from lethal neurological disease.
Taken together, the objective of this proposal is to understand the role of cytokine and MMP-mediated host
inflammatory response in RVF-induced neurological disease, with the ultimate goal of designing therapeutic
interventions to prevent neuropathology. We will address this objective using three complementary specific aims:
In Aim 1, we will determine the kinetic mechanisms by which cytokines and MMPs modulate RVF CNS
inflammation. Aim 2 will develop novel in vitro modeling systems to define RVFV-CNS cell interactions and
screen therapeutic candidates. Aim 3 will test novel therapeutic regimens in a relevant animal model. This
proposal will result in an understanding of the contribution of immunopathology to RVF neurological disease.
Importantly, we will have identified a post-exposure treatment regimen to protect from neurological RVF. This
proposal represents a critical step in the event of an epidemic of this emerging pathogen.
项目摘要/摘要
了解由arbovirus引起的神经系统疾病的发病机理对
使用药物或疫苗疗法治疗病毒脑炎。裂谷热(RVF)是全球重要的
新兴的蚊子传播疾病给人类和牲畜社区带来了重大风险。
由于普遍存在的蚊子载体,全球传播的潜力很高,出现将导致
巨大的经济损害(由于农业影响)以及恐惧和焦虑(由于人类
疾病)。由RVFV引起的最细腻的临床疾病是脑炎,这会导致长期
50%的神经系统症状患者中幸存者的发病率和死亡。该提议建立了
根据我们的初步数据的3个科学发现:1)有适当的脑病动物模型
用野生型RVFV菌株感染后; 2)细胞因子,趋化因子和基质的过量生产
金属蛋白酶(MMP)与神经疾病发作相关; 3)用抗病毒治疗
治疗药物favipiravir是必要的,但不足以保护动物免受致命神经系统疾病的侵害。
综上所述,该提议的目的是了解细胞因子和MMP介导的宿主的作用
RVF引起的神经系统疾病的炎症反应,其最终目的是设计治疗
预防神经病理学的干预措施。我们将使用三个补充特定目标来解决这一目标:
在AIM 1中,我们将确定细胞因子和MMP调节RVF CNS的动力学机制
炎。 AIM 2将开发新型的体外建模系统,以定义RVFV-CNS细胞相互作用和
屏幕治疗候选人。 AIM 3将测试相关动物模型中的新型治疗方案。这
提案将导致对免疫病理学对RVF神经系统疾病的贡献的理解。
重要的是,我们将确定一种暴露后治疗方案,以防止神经RVF。这
在这种新兴病原体流行的情况下,提案代表了关键步骤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy L Hartman其他文献
Amy L Hartman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy L Hartman', 18)}}的其他基金
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses
原型新兴布尼亚病毒感染神经元的机制
- 批准号:
10728597 - 财政年份:2023
- 资助金额:
$ 33.39万 - 项目类别:
Comparative Analysis of Bunyavirus Neuropathogenesis
布尼亚病毒神经发病机制的比较分析
- 批准号:
10675190 - 财政年份:2022
- 资助金额:
$ 33.39万 - 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
- 批准号:
10447151 - 财政年份:2021
- 资助金额:
$ 33.39万 - 项目类别:
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus
新型进入因子Lrp1在裂谷热病毒体内趋向性和发病机制中的作用
- 批准号:
10286235 - 财政年份:2021
- 资助金额:
$ 33.39万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10356824 - 财政年份:2020
- 资助金额:
$ 33.39万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10673312 - 财政年份:2020
- 资助金额:
$ 33.39万 - 项目类别:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
裂谷热减毒活疫苗:经胎盘传播的比较机制和疫苗对发育中胎儿的功效
- 批准号:
10113532 - 财政年份:2020
- 资助金额:
$ 33.39万 - 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
- 批准号:
9002103 - 财政年份:2015
- 资助金额:
$ 33.39万 - 项目类别:
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model
新型大鼠模型中神经致病性裂谷热的机制
- 批准号:
8891769 - 财政年份:2015
- 资助金额:
$ 33.39万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Climate Change Effects on Pregnancy via a Traditional Food
气候变化通过传统食物对怀孕的影响
- 批准号:
10822202 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
- 批准号:
10678789 - 财政年份:2023
- 资助金额:
$ 33.39万 - 项目类别:
Functional, structural, and computational consequences of NMDA receptor ablation at medial prefrontal cortex synapses
内侧前额皮质突触 NMDA 受体消融的功能、结构和计算后果
- 批准号:
10677047 - 财政年份:2023
- 资助金额:
$ 33.39万 - 项目类别:
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
- 批准号:
10702126 - 财政年份:2023
- 资助金额:
$ 33.39万 - 项目类别:
Rapid measurement of novel harm reduction housing on HIV risk, treatment uptake, drug use and supply
快速测量新型减害住房对艾滋病毒风险、治疗接受情况、毒品使用和供应的影响
- 批准号:
10701309 - 财政年份:2023
- 资助金额:
$ 33.39万 - 项目类别: